Prosensa Holding N.V
http://www.prosensa.eu/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Prosensa Holding N.V
Device Classifications For COVID, Acute Febrile Illness IVDs And Force Separation Catheters
The FDA designated class II special controls classifications for two diagnostics and force separation catheters.
Finance Watch: Novartis Sets October Separation Date For Sandoz Spin-Off
Novartis revealed detailed terms and a 4 October spin-off date for Sandoz’s standalone debut. Also, MIRA launched a small IPO, but two firms plan to go public in SPAC mergers. Also, Mirati’s $345m offering leads follow-ons offerings and Sangon Biotech raised $290m in venture capital.
'Constantly Being Chased': Cutting-Edge Gene Therapy Developers Moving Fast In China
Plagued by a scandal which gained global attention a few years go, the gene therapy sector has recovered and is now thriving in China. But a drive for innovation, combined with ready cash for aspiring start-ups, may not translate into leaps and bounds in the field due to challenges unique to these latest treatments, including manufacturing, durability and coverage.
China Gene Therapy Developers Rush To Clinic In 'Winner Takes All' Battle
Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice